Cagrisema is Novo's next-generation combination therapy that pairs the GLP-1 receptor agonist semaglutide with the amylin analogue cagrilintide, and is considered central to the company's efforts to maintain its lead in the fast-growing obesity drug market
Without the glucose-dependent insulin secretion and glucagon suppression provided by GLP-1 medications, HbA1c levels may begin to rise
The early results of these trials look very promising, he said
Over 72 weeks, adults with obesity were randomized to maximum tolerated doses of either tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg): Tirzepatide group: 20.2% mean body weight reduction Semaglutide group: 13.7% mean body weight reduction Tirzepatide also showed greater reduction in waist circumference: 18.4 cm vs
Key Benefits Instant Tone-Up Effect: The cream instantly brightens and evens out your skin
Finally, one of the most overlooked mistakes is failing to train all personnel to the same standard